SPRAVATO™ Patient Experience
what to expect during your treatment
Our Patient Experience
We strive to ensure that our patients have the best treatment session possible. To do this, we provide patients with a relaxing, therapeutic environment free from distractions and which is not overstimulating. Our expert staff will be available throughout your SPRAVATO treatment session to ensure that you receive the care and attention you need, as well as providing pre-care instructions, safety, and post-care advice.
Preparing for Your Treatment
Pre-treatment preparation is one of the most important aspects of a successful SPRAVATO session. Coming into the clinic with the proper mindset completed prep work will ensure your success.
Some helpful tips include bringing a book, tablet, or music with you to your session. Prepare a playlist of relaxing music that helps you get into the right mindset for treatment. Be open and honest with yourself about with objective for your session, setting your intentions for the session.
how it's different
How Does SPRAVATO™ Work?
It is important to note that SPRAVATO is not a standalone medication. It is administered alongside oral anti-depressants.
SPRAVATO must be taken twice a week for the first four weeks. Treatment schedules will then shift to a weekly treatment every four weeks.
Afterward, your healthcare provider will help you determine the best frequency for follow-up applications.
Patient Success Checklist
- Get a full night’s sleep the night before.
- Set your intentions for the session.
- Advise your healthcare provider of any medications you may have taken before your SPRAVATO treatment session. .
- Avoid eating two hours before treatment.
- Do not drink any liquids 30 minutes before your session.
- If applicable, nasal corticosteroids or decongestant medications should be taken at least one hour before SPRAVATO treatments begin.
Post-Session Care
After your SPRAVATO treatment session, your healthcare provider will have you stay for observation for at least two hours. This wait time helps health workers ensure that you do not experience any post-session side effects and gives you time to adjust, process any insights from your session and prepare to head home. Your healthcare provider will discuss any further SPRAVATO treatments with you and help you determine the best course going forward.
How Spravato is Administered
SPRAVATO is delivered in a nasal spray, similar to common nasal decongestants. This delivery method makes SPRAVATO uniquely easy to administer, requiring no IVs or injections. Patients will administer SPRAVATO themselves, with a healthcare professional attending to provide support as needed. Your medical professional will demonstrate how to use the SPRAVATO nasal spray device before treatment properly and will remain on hand to assist you throughout your session.
Safety & Side Effects
SPRAVATO™ nasal spray has been successfully evaluated for safety in short- and long-term clinical trials of adults diagnosed with treatment-resistant depression.
SPRAVATO™ may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space, and time (dissociation).
These side effects may occur right after treatment and typically go away the same day.
References:
- National Institute of Mental Health. Major depression. Updated February 2019. www.nimh.nih.gov/health/statistics/major-depression.shtml#part_155720. Accessed June 3, 2019.
- National Institute of Mental Health. U.S. YLDs contributed by mental and behavioral disorders. www.nimh.nih.gov/health/statistics/disability/us-ylds-contributed-by-mental-and-behavioral-disorders.shtml. Accessed June 11, 2019.
- Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76:155-162.
- Department of Health & Human Services. Does depression increase the risk for suicide? www.hhs.gov/answers/mental-health-and-substance-abuse/does-depression-increase-risk-of-suicide/index.html. Accessed June 4, 2019.
- Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176:428-438.
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917.
- Spravato (esketamine) nasal spray, CIII [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; May 2019.
- National Institute of Mental Health. Mental health medications. Revised October 2016. Accessed June 4, 2019.
- Trivedi MH, Daly EJ. Treatment strategies to improve and sustain remission in major depressive disorder. Dialogues Clin Neurosci. 2008;10:377-384.
- National Institute of Mental Health. Rapidly-acting treatments for treatment-resistant depression (RAPID). www.nimh.nih.gov/research/research-funded-by-nimh/research-initiatives/rapidly-acting-treatments-for-treatment-resistant-depression-rapid.shtml. Accessed June 3, 2019.
